Our findings regarding the enhanced expression of CD80/86 ligands specific for CTLA-4 on the surface of tumor cells from DLBCL patients led us to design a CAR format for CD19/CD80/CD86 expressing B cell lymphomas, to not only improve the efficacy but also the safety of CAR T cell treatment in B cell lymphoma patients. This evidence concerns the gene CD86 and diffuse large B-cell lymphoma.